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Abstract:  Madurahydroxylactone (MHL), a secondary metabolite with antibacterial activity was evaluated for its 
suitability to generate controlled drug release coatings on medical implant materials. A smooth and firmly attached layer 
could be produced from a precursor solution on various metallic implant materials. In physiological salt solutions these 
coatings dissolved within a time period up to one week. A combination of MHL with a broad spectrum fluoroquinolone 
antibiotic was used to create a coating that was active against all bacterial strains tested. The time period during which the 
coating remained active against Pseudomonas aeruginosa was investigated. The results indicated a delayed drug release 
from single layer coatings in the course of seven days. MHL was biocompatible in cell culture assays and could after a 
delay even serve as a cell adhesion substrate for human or murine cells. The findings indicate a potential for MHL for the 
generation of delayed release antimicrobial implant coatings. 
Keywords: Antibacterial, biofilm, cell culture, cell proliferation, in vitro test, infection. 
INTRODUCTION 
  Medical implant infections by a variety of microbes such 
as S. aureus, S. epidermidis, P. aeruginosa, coliforms and 
others still present a significant and a difficult to treat 
clinical problem [1-3]. Immediately after implantation 
various proteins present in blood serum or in other 
extracellular liquids readily adhere to the implant surfaces. It 
is thought that during this early phase after implantation 
before a layer of cells can form, a protective barrier to 
microbial invasion bacteria can most readily colonize the 
implant surfaces by adhering to the material surface or to 
extracellular proteins [4, 5]. When microbes can establish 
themselves on an implant surface they communicate with 
each other. In a process called quorum sensing secreted 
substances coordinate the bacterial behavior depending on 
the cell density. At higher cell densities a biofilm forms 
consisting of bacteria within a matrix of secreted 
polysaccharides. Microbes in biofilms show an increased 
resistance to conventional antibiotic treatments and also to 
the immune defense, whereby the quorum sensing 
substances secreted by the bacteria may act to down-regulate  
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the immune response [6, 7]. Frequently the only effective 
treatment is the removal of the implant followed by 
antibiotic treatment to eliminate the infection [1, 8, 9]. This 
prolongs the suffering of the patient and increases the overall 
treatment costs. Antimicrobial coatings are a promising 
strategy to prevent biofilm formation on implants [10]. Such 
coatings allow high local antibiotic concentrations that are 
essential for the eradication of refractory microbial biofilm 
communities, while dilution effects are keeping systemic 
antibiotic levels below critical toxic values. However, even 
though the time period shortly after implantation is 
considered most critical, bacterial infections can occur well 
after wound healing is completed. Delayed or late implant 
infections are thought to arise by primary infections at other 
sites like the oral cavity and by diverting and weakening the 
immune defense or by direct dissemination of the infectious 
microbes by the blood circulation to the implantation site 
[11-13]. To prevent infections after surgery, basic antibiotic 
implant coatings are not suitable since these are rapidly 
released in a single burst. Consequently, numerous strategies 
have been devised to prolong the efficacious period by 
controlling the release of bioactive substances [14, 15]. 
These include (i) passive coatings whereby anti-adhesive or 
antimicrobial molecules are covalently bonded to the implant 
surface or by using meso-porous surfaces loaded with drugs 
(ii) metallic coatings such as silver that liberate small 
amounts of bactericidal ions for extended periods of time; or 264    The Open Biomedical Engineering Journal, 2010, Volume 4  Badar et al. 
(iii) the release of embedded bioactive substances from a 
slowly degrading matrix such as bone cement or 
hydrolysable organic polymers [16-20]. All strategies have 
specific advantages depending on the application, and also 
serious side effects which highlight the requirement for 
further research [21-23]. After getting into contact with 
blood or other fluids present in the wound covalently bound 
molecules may rapidly be buried and rendered inactive by a 
layer of proteins and other molecules that spontaneously 
adhere to the implant surface. This appears to be the case 
with silver-containing coatings that in vivo are less effective 
than expected; in addition, silver ions exhibit significant 
tissue toxicity [24, 25]. Bone cement with antibiotic 
additions may deteriorate and acidic polymer degradation 
products can cause local inflammation [10]. 
Madurahydroxylactone (MHL), a polysubstituted 
benzo[a]naphthacenequinone, is a secondary metabolite that 
is produced as a mixture of related substances by some 
strains of Nonomuraea  rubra. The red pigmented mixture 
called maduramycin has been reported to be active against 
gram-positive bacteria, [26, 27]. Even though MHL was 
discovered earlier, the correct structure was identified by X-
ray crystallography only in 1994 [26, 28]. Purified MHL has 
a marginal antibacterial activity, it is insoluble in 
physiological salt solutions but readily soluble in DMSO or 
alcohols, and in alkaline aqueous solutions where the lactone 
ring opens and maduranic acid salts can form (Fig. 1A upper 
right) [29]. To investigate the basic feasibility and the release 
characteristics MHL coatings were generated. After drying 
of a precursor solution coatings were obtained on various 
medical implant materials that were firm and biocompatible 
in cell culture assays. With the addition of a conventional 
antibiotic effective antibacterial activity was observed that 
gradually decreased in physiological aqueous solutions 
within a few days. Strategies are discussed that may further 
prolong the useful time period of the coating.  
MATERIALS AND METHODS 
Madurahydroxylactone Preparation 
  The secondary metabolite MHL was produced 
biotechnologically by cultures of the Gram-positive soil 
bacterium Nonomuraea rubra (ATCC 27031, DSM 43768T, 
IMET13001, 16S rDNA: AF277200; basonyms Nonomuria 
rubra, Actinomadura rubra, Microtetraspora rubra, 
Micromonospora rubra [30-33]. MHL was extracted and 
purified using high-performance liquid chromatography 
(HPLC) as described [26-28]. The preparation was stored at -
20 ºC as a dry powder or dissolved in DMSO until it was 
used. 
ESI-MS Analysis of MHL 
  The sample was dried and dissolved in methanol (ca. 3 
pmol/l). An Orbitrap/Velos mass spectrometer (Thermo 
Scientific, Bremen, Germany) equipped with a nanospray 
ion source was used. The spectrum was recorded in the 
positive mode at a resolution of 100 000 and compared with 
the simulated spectrum generated by the Xcalibur (Thermo 
Scientific, USA) software (Fig. 1B and 1C). 
Coating Procedures 
  For biocompatibility testing coatings were prepared as 
follows. A 10 mg/ml MHL solution in dimethyl sulphoxide 
(DMSO) was prepared. Ciprofloxacin (Fluka Chemie 
GmbH, Deisenhofen, Germany) was not soluble in DMSO; 
therefore a fine suspension was prepared at a concentration 
of 10 mg/ml ciprofloxacin in DMSO. The wells of a 12-well 
tissue culture polystyrene (TCPS) plate (BD Falcon, BD 
Biosciences, Germany) were coated with 1l each of the 
MHL solution or with a 1:1 (w/w) mixture of MHL and 
ciprofloxacin. The coatings were dried overnight at room 
temperature. Cells were seeded directly on these coatings 
described below. Zirconium dioxide (zirconia) beads of 1 
mm in diameter (BioSpec Products, Inc., Bartlesville, OK, 
USA) were dip-coated, followed by drying overnight at 
room temperature. Beads dipped in the solvent DMSO were 
used as a control. The release of ciprofloxacin from the 
coatings was determined by submerging the beads in 10l of 
0.1 M phosphate buffered saline (PBS, pH 7.4) in a 
microcentrifuge tube (Eppendorf, Germany) and kept at 
37°C. The liquid was removed at 24h intervals and fresh 
PBS was added to the beads. The resulting ciprofloxacin 
concentration in the supernatants was determined by 
measuring the absorbance at 320nm using a NanoDrop ND-
1000 UV-Vis Spectrophotometer (NanoDrop Technologies, 
Wilmington, USA). MHL released from the coatings was 
calculated similarly by determination of the OD480 of the 
sample supernatant. Titanium, stainless steel (brushed) and 
glass discs of 9mm diameter were coated with a single layer 
of pure MHL dissolved in 70% ethanol at a concentration of 
1 mg/ ml. The discs were put on a hot plate that was set to 
 
Fig. (1). Chemical structure and mass spectrometric analysis of 
madurahydroxylactone.  Chemical structure of MHL 
(3,9,11,14,15-pentahydroxy-7-methoxy-10-methyl-1,3,5,6,8,13-
hexahydronaphthaceno [1,2-f] isobenzofuran-1,8,13-trione) [28]. 
(A). Electrospray ionization mass spectrometry of the 
madurahydroxylactone preparation used throughout the described 
experiments (B) and the simulated mass spectrum for [C26H18O10 
Na]
+ (C) corresponding to the structure depicted in (A). Evaluation of Madurahydroxylactone as a Slow Release  The Open Biomedical Engineering Journal, 2010, Volume 4    265 
90ºC and the plate surface was protected by a household 
aluminum foil. 100 l MHL solution was added with a 
pipette and spread out quickly with the pipette tip until the 
surface was completely covered. After drying the coatings 
were incubated in phosphate buffered saline (PBS) solution 
as described in the text and photographed using a STEMI 
SV11 stereo zoom-microscope (Carl Zeiss, Oberkochen, 
Germany) equipped with a digital camera DSC-S75 (Sony, 
Germany).  
Bacteria 
 The  Escherichia coli laboratory strains Top 10 (F– mcrA 
(mrr-hsdRMS-mcrBC)  80lacZM15  lacX74 recA1 
araD139  (ara leu) 7697 galU galK rpsL (StrR) endA1 
nupG) and DH10B (F– mcrA (mrr-hsdRMS-mcrBC) 
80lacZM15  lacX74 recA1 endA1 araD139 (ara leu) 
7697 galU galK rpsL nupG –), were purchased from 
Invitrogen (Germany). Pseudomonas aeruginosa SCV 20265 
is a small colony variant with increased antibiotic resistance 
that was originally isolated from the lung of a cystic fibrosis 
patient [34, 35]. Pseudomonas aeruginosa strain PA01 
CTX::lux is a laboratory strain that has been made 
luminescent by the insertion of the entire lux operon 
encoding sequence into the genomic DNA [36, 37]. The 
strains S. aureus COL and MRSA are both methicillin 
resistant and their genomes have been completely sequenced 
[38-44]. Bacteria were grown on LB agar dishes or as 
suspension cultures in LB broth according to standard 
procedures [45]. Bacterial growth in suspension cultures was 
monitored by measuring the optical density at 600 nm 
(OD600). The relative bioluminescence of P. aeruginosa 
PAO1 CTX::lux in suspension versus the optical density 
(OD600) was determined by serial dilutions of a fresh 
overnight culture in 100l LB in a 96-well plate at 37º C 
using an optical in vivo imaging system (IVIS-200, Xenogen, 
Alameda, CA).  
  The antibacterial effects of MHL on solid media were 
scored by a radial streak assay. 50g MHL dissolved in 
DMSO (10mg/ml) were placed in the center of a Petri dish 
with LB agar. For comparison, ciprofloxacin (50g) and a 
combination of 25g MHL and 25 g ciprofloxacin and 5l 
of the pure solvent DMSO were put on separate Petri dishes. 
After drying freshly diluted overnight cultures of bacteria 
were radially streaked from the outer rim towards the center 
of the dish and the dishes incubated overnight at 37ºC. The 
antibacterial efficacy was scored by measuring the distance 
of the growth inhibitory zone from the center (Table 1). The 
antibacterial activity released from MHL and ciprofloxacin 
coated zirconia beads was assayed by submerging the beads 
in 50l of LB in a microcentrifuge tube at 37°C. The 
supernatants were collected at 24h intervals and replaced 
with 50l of fresh medium. 45l of each supernatant was 
inoculated in a 96 well plate with 5l of a PAO1 CTX::lux 
culture at an OD600 of 0.2. At the times indicated the 
bacterial luminescence from each sample was determined 
using an IVIS-200 system. To determine the titer of viable 
bacteria aliquots of serial dilutions from each of the 
supernatants were spread on LB agar plates and after 
overnight incubation at 37°C the colonies were counted. All 
experiments were performed in triplicates and the data is 
presented as average value with the standard deviation. 
Mammalian Cells 
  The murine fibroblast cell line NIH 3T3 (ATCC CRL-
1658) and human embryonic kidney cell line HEK 293 
(ATCC CRL-1573) were stored in liquid nitrogen and 
cultured according to standard procedures as previously 
described [46]. NIH 3T3 cells were cultured in Dulbecco’s 
modified Eagle’s Medium (DMEM; Gibco/BRL), 
supplemented with 10% (v/v) fetal calf serum, 1% (v/v) 
glutamine, and 1% (v/v) penicillin and streptomycin (100 
U/ml penicillin G and 100 g/ml streptomycin) at 37°C in a 
humidified atmosphere with 5% CO2. A near confluent 
culture of NIH 3T3 cells was detached using a trypsin 
solution according to standard procedures and diluted 1:5 in 
fresh cell culture medium. 2ml of the cell suspension was 
added to each of the coated wells. After incubating the cells 
in a humidified atmosphere with 5% CO2 at 37°C for 24, 48, 
or 96 h, respectively, the cells were examined using a Zeiss 
Axio Observer A-1 inverted visible light microscope and 
images were recorded using the Axiovision Rel. 4.5 software 
(Carl Zeiss MicroImaging Inc., Germany). The same 
procedure was used for evaluating the biocompatibility of 
Table1.  Bacterial Growth Inhibition by Madurahydroxylactone 
Bacterial strains  Madurahydroxylactone 
inhibition zone 
[mm] 
Ciprofloxacin 
Inhibition zone  
[mm] 
Madurahydroxylactone 
+ ciprofloxacin inhibition zone 
[mm] 
DMSO 
inhibition zone 
[mm] 
Staphylococcus aureus 
(Col) 
1 4.5 6  0 
Staphylococcus aureus 
(MRSA) 
1 4.5  4.5  0 
Escherichia coli (Top 10)  3.5  9  8  0 
Escherichia coli (DH10B)  3  5  4.5  0 
Pseudomonas aeruginosa 
(SCV20265) 
0 6  4.5  0 
Pseudomonas aeruginosa 
(PAO1 CTX::lux) 
0 9 6  0 266    The Open Biomedical Engineering Journal, 2010, Volume 4  Badar et al. 
MHL coatings with HEK 293 cells, except that the culture 
medium used was minimum essential medium (MEM; 
Gibco/BRL) supplemented with 10% fetal calf serum, 1% 
glutamine, 100 U/ml penicillin and 100 g/ml streptomycin. 
All experiments were conducted in triplicates and the results 
are given as mean values with the standard deviation. 
RESULTS 
Confirmation of the Purity and Molecular Mass of the 
MHL Preparation  
  To confirm the purity and the molecular weight of MHL 
as calculated by its chemical structure (Fig. 1A), the dark red 
colored preparation was characterized by electrospray 
ionization mass spectrometry (ESI-MS). An excess of 
sodium ions were added to a methanolic solution to obtain a 
homogeneous sodium salt preparation and to suppress mass 
peaks of other salts. The most abundant molecular weight 
species with a mass of 513.080 agrees well with the 
calculated molecular weight of 513,079 of the sodium adduct 
of MHL (Fig. 1B and C). Minor peaks at 514.084 and 
515,086 correspond to the natural relative abundance and to 
the calculated molecular weight of the compound with one 
or two C12 carbon atoms replaced by the C13 isotope, 
respectively. The peak at m/z 491.098 corresponds to the 
protonated form of the molecule. The nature of the 
remaining mass peaks of substances of minor abundance in 
the preparation was not further investigated. The analysis 
showed that the preparation used was pure and homogeneous 
and in agreement with the corrected MHL structure [28]. 
Preparation of MHL Coatings on Implant Materials 
  For coating microscope cover slips MHL was dissolved 
in DMSO and the solution was dispersed on the glass 
surface. Upon drying a readily visible orange-red colored 
MHL film formed. During drying, more material was 
deposited on the outer rims of the liquid covered area. There 
were no cracks or holes in the resulting coating. Whereas 
spray coating turned out to be comparatively wasteful, a 
more equal distribution was achieved when a MHL solution 
in ethanol was applied with a pipette onto preheated material 
samples. With this technique the most widely used metallic 
implant materials in the clinic, surgical steel and titanium, 
could be coated with a MHL layer with a more homogeneous 
appearance (Fig. 2; M). As an example for a ceramic implant 
material, zirconium dioxide is widely used for tooth repair or 
as replacement prostheses. ZrO2 beads were coated by dip 
coating in a MHL solution in DMSO followed by drying at 
ambient temperatures. The thickness of the resulting layer 
was dependent on the MHL concentration in the precursor 
solution; however, all coatings were firmly attached and had 
a homogeneous, shiny and smooth appearance (Fig. 3). This 
indicates that curved ceramic implant surfaces can be coated 
with a firm layer of MHL. 
Biocompatibility of MHL Coatings  
  The biocompatibility of MHL coatings was investigated 
by monitoring cultures of human and murine cells seeded 
directly on MHL coated glass slides. Cell attachment, cell 
spreading and cell proliferation were evaluated 
microscopically at various time points. Initially cells did not 
attach to MHL coatings, the cells remained rounded and in 
suspension. A few individual rounded cells showed an 
intense red staining (Fig. 4, arrows). 4 days after seeding 
both cell types investigated eventually adhered to the coating 
and showed a spread out physiology (Fig. 4A and 4B). 
Similar to the control, the cells then proliferated on the MHL 
layer until confluence was reached (Fig. 4E). This shows 
that MHL coatings are biocompatible in cell culture assays 
and after some delay they can even serve as a substrate for 
mammalian cell adhesion. 
Antibacterial Efficacy of MHL  
  MHL has been reported to have antimicrobial effects 
against Gram-positive staining bacteria [29]. The 
antibacterial efficacy of MHL was examined with a plate 
assay using Gram-positive S. aureus as well as Gram-
 
Fig. (2). Gradual release of madurahydroxylactone coatings 
from glass and metallic implant materials. Disks of glass (A), 
titanium (B) and stainless steel (C) were coated by placing the 
disks on a hot plate at 90ºC. 100 l of 1 mg/ ml solution of 
madurahydroxylactone in 70% ethanol was added. After the solvent 
was evaporated the disks were incubated in PBS solution and 
pictures of the surface were taken each day until day 5 (1 to 5) at 
magnifications of 0.6x (top rows) and 6.6x magnification (lower 
rows). The scale bars correspond to 5 mm (top rows) and 0.5 mm 
(lower rows) respectively. U, uncoated samples; M, 
Madurahydroxylactone coated samples after drying. 
 
 
Fig. (3). Robust madurahydroxylactone coatings on zirconium 
beads. Zirconium dioxide beads of 1mm diameter were dip coated 
using madurahydroxylactone dissolved in DMSO at 100 mg/ml 
(A), 10mg/ml (B), 1mg/ml (C), DMSO (D) and dried at ambient 
temperature. The scale bar corresponds to 0.2 mm. Evaluation of Madurahydroxylactone as a Slow Release  The Open Biomedical Engineering Journal, 2010, Volume 4    267 
negative E. coli laboratory strains and P. aeruginosa, a drug-
resistant biofilm forming pathogen. All bacterial strains 
tested were highly resistant to MHL in plate assays (Table 
1). Since MHL showed promising properties as a slow 
release coating but only limited effects against bacteria, 
combinations with a well established antibiotic with proven 
activity were used to increase the antibacterial efficacy of the 
coatings. Among various MHL to ciprofloxacin ratios tested, 
the 1:1 (w/w) mixture formed a well adhering coating and 
was highly effective against all bacterial strains tested (Table 
1). Therefore, it was selected for further investigations. 
Release Characteristics of MHL Coatings  
  The coating remained attached to these materials even 
after immersion in a phosphate buffered solution (Fig. 2). To 
determine the stability of the coatings under physiological 
conditions the MHL  coated implant material discs were 
incubated in PBS at 37°C and 5% CO2 atmosphere in a cell 
culture incubator with a daily exchange of the supernatant. 
The single layer coatings gradually dissolved in the course of 
one to two weeks while remaining attached to the metal 
surface (Fig. 2). In contrast, under these conditions flakes of 
the coating peeled off from the glass surfaces that were used 
 
Fig. (4). Biocompatibility and delayed adherence of cultured 
cells on madurahydroxylactone coatings. NIH3T3 cells (A and 
C) and HEK 293 cells (B and D) were seeded on glass microscope 
cover slips coated with a 1:1 (w/w) mixture of madurahydroxy-
lactone with ciprofloxacin (A and B) or without coating (C and D). 
The cells were cultured in DMEM with 10% FCS under standard 
conditions and microphotography images were taken after 1, 2 or 4 
days as indicated. The scale bar corresponds to 100 m. The white 
arrows point out red stained cells. HEK 293 cell density after 
incubation for the time indicated on the following surfaces: CCP 
(black bars), glass (gray bars), MHL (empty bars) (E). 
 
 
 
Fig. (5). Delayed release of ciprofloxacin from 
madurahydroxylactone coatings. The specific absorption of 
ciprofloxacin (A) and madurahydroxylactone (B) in PBS at 320 nm 
and 480 nm, respectively, was determined by a linear regression 
analysis. Time dependent ciprofloxacin release from zirconium 
bead coatings with ciprofloxacin (squares); release from mixed 
coatings containing ciprofloxacin and madurahydroxylactone 
(triangles) or from the dried solvent DMSO (crosses); release of 
madurahydroxylactone from madurahydroxylactone coatings 
(diamonds). The coated beads were incubated in PBS at 37ºC. The 
buffer was exchanged each day and the OD480 and OD320 
determined to calculate the release of ciprofloxacin and 
madurahydroxylactone, respectively (C). 
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here as controls, indicating a less firm attachment to this 
material. These results show that MHL fulfills some basic 
criteria for applications as a slow release coating for metallic 
implants with a time course that limits its suitability to some 
specific short-term applications.  
  To determine the characteristics of the coating on 
zirconium dioxide beads these were incubated in a 
physiological phosphate buffer, whereby the buffer was 
exchanged at daily intervals. The ciprofloxacin and MHL 
concentrations in the supernatant could be determined by 
measuring the absorption at 320 nm and 480 nm, 
respectively, with a nearly linear correlation of the optical 
density and the concentration within the range investigated 
(Fig. 5A and 5B). The release of pure MHL from coatings 
was even slower whereas ciprofloxacin from coatings 
without MHL was largely dissolved in one initial burst on 
the first day (Fig. 5C). The concentration of ciprofloxacin 
released from the mixed coating with MHL was highest in 
the first day of the experiment and decreased gradually until 
day 3 when the absorption reached background levels and 
was no longer detectable. Therefore, for measuring the small 
amounts released after longer incubation periods the 
absorption measurements were not sensitive enough.  
  To establish a more sensitive antibiotic release scoring 
method genetically engineered luminescent Pseudomonas 
aeruginosa bacteria were used. This allowed the contact-free 
quantification of the antibacterial effects in small assay 
volumes. The luminescence was linear proportional to the 
viable bacterial cell density over a wide range of several 
orders of magnitude (Fig. 6). Therefore the luminescence 
could be directly used as a measure of cell growth and 
viability. Using this assay the supernatant from the beads 
coated with a 1:1 (w/w) mixture of MHL and ciprofloxacin 
significantly inhibited bacterial proliferation until day 7 (Fig. 
7). The highest efficacy was observed during the first day, 
with a gradual decrease over the time of the experiment and 
resulting in a marginal antibacterial effect at day 7. In 
contrast, the bactericidal effect of a pure ciprofloxacin 
coating was reduced over 90% after one day incubation. This 
is in good agreement with the absorption measurements of 
the supernatant of the incubation buffer, showing that this 
test was suitable and sufficiently sensitive. The results 
indicated that the combined coating of ciprofloxacin with 
MHL was gradually released when exposed to an aqueous 
environment. 
 
Fig. (7). Prolonged antibacterial activity of MHL coatings with 
ciprofloxacin. Zirconium dioxide beads coated with a 1:1 (w/w) 
mixture of MHL with ciprofloxacin were incubated for 7 days in 
LB medium with daily exchange of the medium. The medium was 
inoculated with luminescent P. aeruginosa and the luminescence of 
the cultures after 5 hrs incubation at 37ºC is shown. The 
supernatants were incubated with beads coated with MHL (filled 
circles), ciprofloxacin (open circles), DMSO (open triangles) or a 
combination of ciprofloxacin with MHL (filled triangles).  
DISCUSSION 
  Structurally related derivatives of MHL have been 
synthesized with an enhanced antimicrobial activity and 
were proposed as slow release antibiotic coatings for medical 
implants [29, 47]. However, the efficacy of these compounds 
was limited. A test using luminescently labeled bacteria was 
established for real-time monitoring of the antimicrobial 
activity of novel implant coatings. The advantages of this 
assay are that unlike microscopic techniques, it requires no 
staining procedures or other sample preparation, it works 
with opaque or fluorescent implant materials, it yields 
quantitative numerical data of the same samples over time 
and when using microtiter plates several hundred samples 
can be evaluated contactless, in parallel in a single 
measurement. Our data shows that MHL is a chemical 
compound with properties that appear suitable as a basis for 
implant coatings. MHL coatings did not peel off; they 
remained bound to the implant surface and were gradually 
dissolved in physiologically buffered aqueous solutions. 
MHL was highly biocompatible in cell culture assays, which 
is consistent with the low toxicity observed in mice with a 
reported LC50 greater than 250 mg/kg intraperitoneally [26]. 
The fact that cultured cells adhere to MHL coatings with a 
delay is not necessarily related to biocompatibility. A 
possible explanation would be that the cell culture medium 
exposed MHL surface layer may change its characteristics 
by absorbing lipophilic molecules such as serum albumin 
[26]. The finding that initially individual floating cells at the 
 
Fig. (6). Linear relationship between bacterial concentration 
and luminescence. Correlation of P. aeruginosa PA01 CTX::lux 
strain luminescence (radiance) and OD600 of the culture with the 
titer of bacterial colony forming units (CFU/ml). 
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border of the coating appeared intensively red stained 
suggests that these cells were in close contact with the MHL 
layer and visible amounts of MHL were bound to the cell 
membrane or were taken up by these cells. A highly 
biocompatible behavior may be of advantage compared to 
some of the presently used slow release implant materials. In 
particular, various degradable organic polymers have been 
reported to cause inflammation and even bone cement 
degradation may result in the accumulation of inflammatory 
particulate debris [48-52]. It has been demonstrated that drug 
combinations with ciprofloxacin can have synergistic effects 
on implant associated biofilms of the major clinically 
relevant bacterial species [53]. Therefore, we prepared MHL 
coatings with additions of ciprofloxacin which remained 
efficacious for a few days in aqueous solutions. This time 
period is within the range that has been observed with related 
coating techniques and appears promising to prevent 
nosocomial infections [54-56]. However, an extension of the 
effective time period could be of advantage, since implant 
infections have been reported to occasionally occur not only 
during surgery but even well after the wound has healed, 
possibly by pathogens that are disseminated in the body via 
the blood circulation [57]. There are various strategies by 
which the effective time span of the coating could be further 
extended, for example by applying thicker layers, by 
multilayered coatings or by loading the antibiotic into the 
cavities of implants with porous surface structures [47, 58, 
59].  
CONCLUSION 
  MHL was used as a basis to generate antimicrobial 
delayed drug release coatings on various medical implant 
materials. A luminescent bacteria assay has been established 
that facilitated the evaluation of the antimicrobial efficacy. 
The results show that MHL-based coatings have promising 
physical and biological properties to prevent nosocomial 
implant infections at least during the most risky period up to 
one week after surgery. 
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